MDPI and ACS Style
Bartoletti, M.; Giorda, G.; Viel, A.; Fornasarig, M.; Zdjelar, A.; Segatto, E.; Sorio, R.; Corsetti, S.; Scalone, S.; Nicoloso, M.S.;
et al. An Exceptional Response to Dostarlimab in Mismatch Repair Deficient, Microsatellite Instability-High and Platinum Refractory Endometrial Cancer. Curr. Oncol. 2022, 29, 5209-5212.
https://doi.org/10.3390/curroncol29080413
AMA Style
Bartoletti M, Giorda G, Viel A, Fornasarig M, Zdjelar A, Segatto E, Sorio R, Corsetti S, Scalone S, Nicoloso MS,
et al. An Exceptional Response to Dostarlimab in Mismatch Repair Deficient, Microsatellite Instability-High and Platinum Refractory Endometrial Cancer. Current Oncology. 2022; 29(8):5209-5212.
https://doi.org/10.3390/curroncol29080413
Chicago/Turabian Style
Bartoletti, Michele, Giorgio Giorda, Alessandra Viel, Mara Fornasarig, Adrian Zdjelar, Enrica Segatto, Roberto Sorio, Serena Corsetti, Simona Scalone, Milena Sabrina Nicoloso,
and et al. 2022. "An Exceptional Response to Dostarlimab in Mismatch Repair Deficient, Microsatellite Instability-High and Platinum Refractory Endometrial Cancer" Current Oncology 29, no. 8: 5209-5212.
https://doi.org/10.3390/curroncol29080413